Prevents osteoporosis in postmenopausal women ( 1.1, 1.2 ). ANDA 75710, held by Impax Labs Inc. Alendronate Sodium.
As of Nov 16, 2026, ANDA 75710 (Alendronate Sodium), held by Impax Labs Inc, was first approved by FDA on Feb 6, 2008, with 11 approved supplements and 0 published complete response letters.
Alendronate sodium tablets are a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women ( 1.1, 1.2 ) Treatment to increase bone mass in men with osteoporosis Treatment of glucocorticoid-induced osteoporosis Treatment of Paget's disease of bone Limitations of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. 1.1 Treatment of Osteoporosis in Postmenopausal Women Alendronate sodium tablets are indicated for the treatment of osteoporosis in postmenopausal women.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 6, 2008 | Original application | Approved |
| Alendronate SodiumEQ 5MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 10MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 35MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 40MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 70MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Apr 23, 2026 | Supplement 25Labeling · Standard review | Approved | None posted |
| Jan 31, 2023 | Supplement 22Labeling · Standard review | Approved | None posted |
| Mar 29, 2016 | Supplement 18Labeling · Standard review | Approved | None posted |
| Jul 16, 2015 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jul 16, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jul 15, 2013 | Supplement 9Manufacturing | Approved | None posted |
| May 22, 2012 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 1, 2011 | Supplement 8Labeling | Approved | None posted |
| Apr 22, 2010 | Supplement 4Labeling | Approved | None posted |
| Oct 20, 2009 | Supplement 3Labeling | Approved | None posted |
| Jan 23, 2009 | Supplement 1Labeling | Approved | None posted |
| Feb 6, 2008 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters